This company has been acquired
Ayala Pharmaceuticals Management
Management criteria checks 3/4
Key information
Roni Mamluk
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 23.18% |
| CEO tenure | 5.2yrs |
| CEO ownership | 1.9% |
| Management average tenure | 3.6yrs |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
Ayala stock rises 12% on FDA fast track status for AL102 for desmoid tumors
Sep 27Ayala Pharma rises on positive data from phase 2/3 trial of AL102 in desmoid tumors
Sep 12Here's Why Ayala Pharmaceuticals (NASDAQ:AYLA) Must Use Its Cash Wisely
Jul 28
Here's Why We're A Bit Worried About Ayala Pharmaceuticals' (NASDAQ:AYLA) Cash Burn Situation
Mar 19Will Ayala Pharmaceuticals (NASDAQ:AYLA) Spend Its Cash Wisely?
Sep 11We Think Ayala Pharmaceuticals (NASDAQ:AYLA) Needs To Drive Business Growth Carefully
Jun 04Here's Why We're Not Too Worried About Ayala Pharmaceuticals' (NASDAQ:AYLA) Cash Burn Situation
Feb 19Need To Know: Analysts Are Much More Bullish On Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Revenues
Nov 20
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$38m |
| Jun 30 2022 | n/a | n/a | -US$38m |
| Mar 31 2022 | n/a | n/a | -US$41m |
| Dec 31 2021 | US$2m | US$388k | -US$40m |
| Sep 30 2021 | n/a | n/a | -US$40m |
| Jun 30 2021 | n/a | n/a | -US$37m |
| Mar 31 2021 | n/a | n/a | -US$33m |
| Dec 31 2020 | US$2m | US$362k | -US$30m |
| Sep 30 2020 | n/a | n/a | -US$26m |
| Jun 30 2020 | n/a | n/a | -US$24m |
| Mar 31 2020 | n/a | n/a | -US$21m |
| Dec 31 2019 | US$698k | US$249k | -US$18m |
Compensation vs Market: Roni's total compensation ($USD1.67M) is above average for companies of similar size in the US market ($USD730.59K).
Compensation vs Earnings: Roni's compensation has been consistent with company performance over the past year.
CEO
Roni Mamluk (55 yo)
Dr. Roni Mamluk, Ph D., M.D, serves as Venture Advisor at Israel Biotech Fund since 2018. Dr. Mamluk serves as the Chief Executive Officer, President and Director of Ayala Pharmaceuticals Inc. since Novemb...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.2yrs | US$1.67m | 1.86% $ 133.6k | |
| CFO, Secretary & Treasurer | 3.8yrs | US$801.54k | 0.49% $ 35.2k | |
| Chief Medical Officer | 3.4yrs | US$822.51k | 0.41% $ 29.5k | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Vice President of Human Resources | no data | no data | no data | |
| Chief Business Officer | no data | no data | no data |
Experienced Management: AYLA's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.2yrs | US$1.67m | 1.86% $ 133.6k | |
| Independent Director | 5.1yrs | US$84.98k | 0% $ 0 | |
| Independent Chairman of the Board of Directors | 5.2yrs | US$154.97k | 0.0018% $ 126.0 | |
| Independent Director | 5.1yrs | US$77.48k | 0% $ 0 | |
| Independent Director | 2.4yrs | US$79.98k | 0% $ 0 |
Experienced Board: AYLA's board of directors are considered experienced (5.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/01/21 13:35 |
| End of Day Share Price | 2023/01/18 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ayala Pharmaceuticals, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maurice Raycroft | Jefferies LLC |
| Ahu Demir | Ladenburg Thalmann & Company |
| Naureen Quibria | Maxim Group |